Understand the source comparison
Peptide Dosing Protocols: Clinical vs Underground
Dosing protocols for longevity peptides exist on a spectrum from clinically validated to entirely speculative. Understanding where a given protocol falls on that spectrum determines whether you're following evidence-based medicine or participating in an uncont
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dosing protocols for longevity peptides exist on a spectrum from clinically validated to entirely speculative. Understanding where a given protocol falls on that spectrum determines whether you're following evidence-based medicine or participating in an uncontrolled self-experiment.
- Clinically derived protocols. Those extracted from published human trials. Exist for only a handful of compounds. Epitalon's standard protocol (10mg subcutaneous daily for 10 days, repeated 1–2 times per year) comes directly from Russian gerontology studies. Thymalin dosing (10mg intramuscular daily for 10 days annually) follows the same structure used in immune senescence trials. MK 677 dosing (25mg oral daily) mirrors the dose used in Phase III sarcopenia trials. These protocols have safety data attached. Researchers monitored adverse events, measured hormone panels, and tracked discontinuation rates.
- Extrapolated protocols. Derived from animal studies using allometric scaling. Represent the majority of longevity peptide dosing. BPC-157, widely used for tissue repair and gut healing, has no published human dosing trials despite extensive rat data. The common human dose (250–500mcg subcutaneous twice daily) is scaled from rodent studies using body surface area formulas, which assume linear dose translation between species. That assumption may or may not hold. Peptides with narrow therapeutic windows or species-specific metabolism may require entirely different human doses than allometric scaling predicts.
- Underground protocols. Dosing schedules shared on forums with no published basis. Are the riskiest category. These often combine multiple peptides simultaneously ('stacks') based on theoretical synergy rather than controlled interaction studies. Combining Dihexa for cognitive enhancement with growth hormone secretagogues for body composition might seem logical, but without pharmacokinetic interaction data, you're guessing whether one compound affects the other's metabolism, receptor binding, or adverse event profile.
- Our experience working with research teams: start with clinically validated protocols where they exist, and when extrapolating from animal data, begin at the lowest dose predicted by allometric scaling rather than the highest.